GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » Interest Coverage

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Interest Coverage : 0 (At Loss) (As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Adamas Pharmaceuticals's Operating Income for the three months ended in Sep. 2021 was $-5.64 Mil. Adamas Pharmaceuticals's Interest Expense for the three months ended in Sep. 2021 was $-13.88 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Adamas Pharmaceuticals's Interest Coverage or its related term are showing as below:


ADMS's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.56
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Adamas Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Adamas Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Adamas Pharmaceuticals Interest Coverage Chart

Adamas Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Interest Coverage
Get a 7-Day Free Trial Premium Member Only No Debt - - - -

Adamas Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adamas Pharmaceuticals's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Adamas Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adamas Pharmaceuticals's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adamas Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Adamas Pharmaceuticals's Interest Coverage falls into.



Adamas Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Adamas Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Adamas Pharmaceuticals's Interest Expense was $-13.24 Mil. Its Operating Income was $-44.16 Mil. And its Long-Term Debt & Capital Lease Obligation was $132.76 Mil.

Adamas Pharmaceuticals did not have earnings to cover the interest expense.

Adamas Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2021 is calculated as

Here, for the three months ended in Sep. 2021, Adamas Pharmaceuticals's Interest Expense was $-13.88 Mil. Its Operating Income was $-5.64 Mil. And its Long-Term Debt & Capital Lease Obligation was $129.58 Mil.

Adamas Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Adamas Pharmaceuticals  (NAS:ADMS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Adamas Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Executives
Vijay Shreedhar officer: Chief Commercial Officer C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss officer: Chief Financial Officer 1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson director, 10 percent owner 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee director C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg director 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane officer: Chief Executive Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather officer: Chief Financial Officer
Jennifer J Rhodes officer: CBO, GC & Compliance Officer C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went director, officer: Chief Executive Officer C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni officer: Chief Medical Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Headlines

From GuruFocus

Adamas Announces New Employment Inducement Grants

By Business Wire Business Wire 09-10-2021